v3.26.1
Shareholder's Deficit (Details) - USD ($)
 1 Months Ended 12 Months Ended
Aug. 28, 2025
Dec. 31, 2025
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Shareholder’s Deficit [Line Items]            
Authorized shares [1]   500,000,000 500,000,000 500,000,000    
Ordinary shares, par value (in Dollars per share) [1]   $ 0.0001 $ 0.0001 $ 0.0001    
Ordinary shares, issued [1]   70,789,261 70,789,261 64,730,411    
Increase of PIPE financing (in Dollars)     $ 13,200,000 $ 7,545,772  
Ordinary shares, outstanding [1]   70,789,261 70,789,261 64,730,411    
Public Warrants [Member]            
Shareholder’s Deficit [Line Items]            
Exercise price (in Dollars per share)   $ 0.99 $ 0.99      
Warrants were exchanged   62,580 62,580      
Investor [Member]            
Shareholder’s Deficit [Line Items]            
Increase of PIPE financing (in Dollars) $ 13,200,000          
Private Investment in Public Equity [Member]            
Shareholder’s Deficit [Line Items]            
Shares issue price per share (in Dollars per share) $ 8          
YD Biopharma [Member]            
Shareholder’s Deficit [Line Items]            
Business combination outstanding shares 4,140,948   4,140,948      
YD Biopharma [Member] | Public Warrants [Member]            
Shareholder’s Deficit [Line Items]            
Business combination outstanding shares   62,580        
Common Stock [Member]            
Shareholder’s Deficit [Line Items]            
Authorized shares   500,000,000 500,000,000      
Ordinary shares, par value (in Dollars per share)   $ 0.0001 $ 0.0001      
Number voting     one      
Warrants were exchanged   205,333 205,333      
Ordinary shares, outstanding 70,521,359 70,789,261 70,789,261 64,730,411 64,730,411 64,730,411
Common Stock [Member] | Public Warrants [Member]            
Shareholder’s Deficit [Line Items]            
Exercise price (in Dollars per share)   $ 11.5 $ 11.5      
Warrants were exchanged   1,782,089 1,782,089      
Common Stock [Member] | Private Investment in Public Equity [Member]            
Shareholder’s Deficit [Line Items]            
Issue ordinary shares 1,650,000          
Common Stock [Member] | YD Biopharma [Member]            
Shareholder’s Deficit [Line Items]            
Business combination outstanding shares 64,730,411          
Ordinary shares, issued   64,730,411 64,730,411      
[1] Shares related information and additional paid-in capital are retrospectively restated for effect of recapitalization completed on August 28, 2025.